科伦博泰公布TROP2 ADC治疗尿路上皮癌2期临床结果

医药地理11-29

11月28日，科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗（sac-TMT，佳泰莱®）单药治疗晚期或转移性尿路上皮癌（UC）患者的临床研究数据荣登国际知名学术期刊Annals of Oncology(《肿瘤学年鉴》，影响因子IF=65.4)。这项研究首次证实了芦康沙妥珠单抗(sac-TMT)在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗（sac-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2587475778?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-29 15:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2587475778","market":"hk","top_or_hot":-1,"title":"科伦博泰公布TROP2 ADC治疗尿路上皮癌2期临床结果","media":"医药地理","content":"<div>\n<p>11月28日，科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗（sac-TMT，佳泰莱®）单药治疗晚期或转移性尿路上皮癌（UC）患者的临床研究数据荣登国际知名学术期刊Annals of Oncology(《肿瘤学年鉴》，影响因子IF=65.4)。这项研究首次证实了芦康沙妥珠单抗(sac-TMT)在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗（sac-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129155121a7190857&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦博泰公布TROP2 ADC治疗尿路上皮癌2期临床结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦博泰公布TROP2 ADC治疗尿路上皮癌2期临床结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-29 15:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129155121a7190857&s=b><strong>医药地理</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月28日，科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗（sac-TMT，佳泰莱®）单药治疗晚期或转移性尿路上皮癌（UC）患者的临床研究数据荣登国际知名学术期刊Annals of Oncology(《肿瘤学年鉴》，影响因子IF=65.4)。这项研究首次证实了芦康沙妥珠单抗(sac-TMT)在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗（sac-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129155121a7190857&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129155121a7190857&s=b","article_id":"2587475778","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129155121a7190857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2587475778","pubTimestamp":1764402539,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月28日，科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗单药治疗晚期或转移性尿路上皮癌患者的临床研究数据荣登国际知名学术期刊Annals of Oncology。这项研究首次证实了芦康沙妥珠单抗在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗单药治疗经化疗和免疫检查点抑制剂治疗进展的晚期或转移性尿路上皮癌疗效及安全性的Ⅱ期临床研究队列9的结果。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","06990":"科伦博泰生物-B","BK1161":"生物科技"},"translate_title":"Kelunbotai announces phase 2 clinical results of TROP2 ADC in the treatment of urothelial cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9},"content_text":"11月28日，科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗（sac-TMT，佳泰莱®）单药治疗晚期或转移性尿路上皮癌（UC）患者的临床研究数据荣登国际知名学术期刊Annals of Oncology(《肿瘤学年鉴》，影响因子IF=65.4)。这项研究首次证实了芦康沙妥珠单抗(sac-TMT)在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗（sac-TMT）单药治疗经化疗和免疫检查点抑制剂治疗进展的晚期或转移性尿路上皮癌疗效及安全性的Ⅱ期临床研究（MK-2870-001/KL264-01）队列9的结果。研究结果显示，芦康沙妥珠单抗（sac-TMT）(5mg/kg，每2周一次）单药治疗在经重度治疗的晚期或转移性尿路上皮癌患者中显示出令人鼓舞的抗肿瘤活性，安全性可控，该研究结果支持芦康沙妥珠单抗（sac-TMT）在晚期UC人群中进一步探索。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2587475778","isCrawlerRequest":true}